2021
DOI: 10.1080/10408363.2021.1942781
|View full text |Cite
|
Sign up to set email alerts
|

Molecular tissue profiling by MALDI imaging: recent progress and applications in cancer research

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
16
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 27 publications
(20 citation statements)
references
References 133 publications
1
16
0
Order By: Relevance
“…Here, analysis of so-called "learning curves" in the related domain of micro-array analysis [124,125] have shown promise in determining effective sample sizes [126], and a minimum of 75 specimens per class have been suggested [127]. Here, there are parallels to draw from proteomics using Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-MS) profiling [128][129][130][131], where guidelines for determining the appropriate sample size for clinical proteomic profiling studies have been put forward, using a linear mixed model that allows for the inclusion of estimates of biological and technical replicate variance in a given experiment [132]. In a similar vein, by extending previously published approaches [133,134], the effect of biological variance (e.g., intratumoural heterogeneity), as an important determinant of the overall sample size required, has been examined towards a method that allows for the adjustment of expected biological variance in calculations of sample size [135].…”
Section: Initial Statistical Modeling Should Be Based On Sufficient Sample Numbersmentioning
confidence: 99%
“…Here, analysis of so-called "learning curves" in the related domain of micro-array analysis [124,125] have shown promise in determining effective sample sizes [126], and a minimum of 75 specimens per class have been suggested [127]. Here, there are parallels to draw from proteomics using Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-MS) profiling [128][129][130][131], where guidelines for determining the appropriate sample size for clinical proteomic profiling studies have been put forward, using a linear mixed model that allows for the inclusion of estimates of biological and technical replicate variance in a given experiment [132]. In a similar vein, by extending previously published approaches [133,134], the effect of biological variance (e.g., intratumoural heterogeneity), as an important determinant of the overall sample size required, has been examined towards a method that allows for the adjustment of expected biological variance in calculations of sample size [135].…”
Section: Initial Statistical Modeling Should Be Based On Sufficient Sample Numbersmentioning
confidence: 99%
“…All these feature makes MALDI the ideal technique for routine clinical analysis, as demonstrated by the huge number of existing applications for diagnostic purposes [ 19 , 20 , 21 ]. MALDI has indeed demonstrated a great potential when applied to the fight against cancer [ 22 ], and part of the huge amount of work performed on tumor-related topics, including the analysis of drugs [ 23 ], MALDI-imaging developments [ 24 , 25 ], diagnosis of ovarian [ 26 ], non-small cell lung [ 27 ], and prostate [ 28 ] cancer, has very recently been reviewed.…”
Section: Introductionmentioning
confidence: 99%
“…Coupling data on molecular profiles to advanced data processing algorithms facilitates the development of platforms for various goals. Analysis and comparison of the levels of small biomolecules in the organism can be useful in studies of metabolomics [6], the search for cancer biomarkers [7], disease pathogenesis [8], differentiation between stages [9], reasonable prognosis and the careful selection of the treatment strategy [10].…”
Section: Introductionmentioning
confidence: 99%